Vasoprotection and antihypertensive therapy
作者:
Philip Henry,
Olga Cabello,
期刊:
Current Opinion in Nephrology and Hypertension
(OVID Available online 1995)
卷期:
Volume 4,
issue 2
页码: 197-200
ISSN:1062-4821
年代: 1995
出版商: OVID
数据来源: OVID
摘要:
Vasoprotective drugs decrease the vulnerability of blood vessels to cardiovascular risk factors such as hypertension and hypercholesterolemia. Mechanistic treatment end-points of hypertension (normalization of endovascular pressure) may not correct non hypertensive components of the pathobiology of hypertension. Estrogen replacement therapy, antihypertensive treatment with angiotensin-converting enzyme inhibitors, and manipulations of nitric oxide metabolism may have beneficial effects on vessels in the absence of blood pressure normalization. Estrogens and L-arginine, the precursor of nitric oxide, can partly correct impaired endothelium-dependent vasodilation, a pathophysiologic hallmark of hypertensive states. Angiotensin-converting enzyme inhibitors preserve endothelium-dependent vasodilation and protect arteries against the atherogenic effects of hypercholesterolemia by a non-hypolipidemic, non-hypotensive mechanism.
点击下载:
PDF
(413KB)
返 回